Tharimmune Inc. Board Shakeup: New Directors, CFO Appointed
Ticker: CNTN · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1861657
| Field | Detail |
|---|---|
| Company | Tharimmune, INC. (CNTN) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $300,000, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-appointment
TL;DR
Tharimmune's board is changing: Hunt out, Kelly & Johnson in as directors, Johnson also named CFO.
AI Summary
On December 10, 2025, Tharimmune, Inc. announced the departure of Dr. Jonathan T. Hunt from its Board of Directors. The company also elected Ms. Sarah E. Kelly and Mr. David M. S. Johnson as new directors. Additionally, Mr. David M. S. Johnson was appointed as the Chief Financial Officer.
Why It Matters
Changes in board composition and executive leadership can signal strategic shifts or governance adjustments within the company.
Risk Assessment
Risk Level: medium — Changes in board and executive roles can indicate internal shifts that may impact future strategy and performance.
Key Players & Entities
- Tharimmune, Inc. (company) — Registrant
- Dr. Jonathan T. Hunt (person) — Departing Director
- Ms. Sarah E. Kelly (person) — Newly Elected Director
- Mr. David M. S. Johnson (person) — Newly Elected Director and CFO
FAQ
Who has departed from Tharimmune's Board of Directors?
Dr. Jonathan T. Hunt has departed from Tharimmune's Board of Directors.
Who has been elected as new directors to Tharimmune's Board?
Ms. Sarah E. Kelly and Mr. David M. S. Johnson have been elected as new directors.
What is Mr. David M. S. Johnson's new role in the company?
Mr. David M. S. Johnson has been appointed as the Chief Financial Officer (CFO) of Tharimmune, in addition to being a director.
What is the exact date of the reported events?
The earliest event reported is dated December 10, 2025.
What is Tharimmune, Inc.'s Standard Industrial Classification (SIC) code?
Tharimmune, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,382 words · 6 min read · ~5 pages · Grade level 11.8 · Accepted 2025-12-12 08:45:36
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value THAR The Nasdaq Stock Mar
- $300,000 — o receive: (i) an annual base salary of $300,000, subject to review and adjustment by th
- $100,000 — scretion, with a target amount equal to $100,000, subject to continuous employment with
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex10-1.htm (EX-10.1) — 103KB
- ex99-1.htm (EX-99.1) — 13KB
- 0001493152-25-027373.txt ( ) — 358KB
- thar-20251210.xsd (EX-101.SCH) — 3KB
- thar-20251210_lab.xml (EX-101.LAB) — 33KB
- thar-20251210_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 12, 2025 Tharimmune, Inc. /s/ Mark Wendland Mark Wendland Chief Executive Officer -4-